Breakthrough transplants signal a GREAT opportunity

MY NUMBER 1 RECOMMENDATION TO CREATE FULL TIME INCOME ONLINE: CLICK HERE

Currently, large technology companies are pouring money into healthcare startups. Google (NASDAQ:GOOG, NASDAQ:GOOGL), Apple (NASDAQ:AAPL), Oracle (NYSE:ORCL), Amazon (NASDAQ:AMZN) in Microsoft (NASDAQ:IFFT) invest in and acquire healthcare companies like never before …

Source: shutterstock.com/MAD.vertise

This is a great tip for investors who want to stay ahead of trends in venture capital deals.

Like I said in December:

“If we look at the takeover trends of big companies, we can not only look to the future where the trends are moving, but we are also positioning ourselves as investors to be on the path to progress.”

Since we know there are a huge number of customers out there (high technology), private investment in healthcare is likely to be good in the near future.

What if we could invest in opportunities before the big players get involved?

What signs can we look for to show that the industry is just about to take off … but is still small enough to make big profits in the years to come?

This is what we currently have in terms of longevity.

Investing in longevity will be one of the biggest investment trends we have ever seen.

And as the development of this boom in longevity materializes, the world will change in ways you won’t be able to believe …

Interspecific transplants could become the norm

“The first transplant of a pig’s heart genetically modified for acceptance into the human body” in the world was conducted last week. And so far this is a success.

The operation was performed at the University of Maryland Medical Center on a 57-year-old man who, due to poor health, was not suitable for a traditional human-to-human transplant.

“Die or do this procedure,” said the man, who received a pig heart and whose body has since accepted the transplanted heart without rejection.

This only happens months after the doctors are at NYU Langone Health in New York has been announced that a human kidney kidney has been successfully transplanted.

Both procedures have been experimental and require special permission from U.S. health regulators.

You see, xenotransplantation, which is an area of ​​organ transplantation between different species, it was previously impossible whereas “the movement of an organ from one species to another provokes a violent and immediate attack by the host’s immune system,” says science magazine.

However, in the two xenotransplants I just mentioned, these organs have been genetically modified to rule out certain genes that the human body normally rejects. This allows the human body to be “tricked” into accepting foreign organs and using them as if they were from another human being.

With two successful (so far) transplants performed, plans are underway to begin clinical trials of this new type of organ transplant technology.

The process of changing genes in pig organs is scratching the surface of what many biotechnology companies are now researching …

You’ve probably heard of gene editing before. Gene editing is the process of changing the DNA sequence of an organism. This technology allows the addition, removal or modification of genetic material for various purposes, such as transplanting organs from one species to another.

It is difficult to understand the consequences that gene regulation will have on our human species (and all other organisms with DNA). Theoretically, by editing DNA, we can do everything from treating cancer to improving vision to living longer.

And living longer is something people are willing to pay big money for.

Private money is flowing

Last month, a new venture capital fund, Korify Capital, announced it would investing $ 100 million in a long-lived startup company.

“Coryphaeus join several other investors in the longevity space, including the Berlin VC and the founder of Apollo Health Ventures, which successfully raised $ 180 million in November. The other two are the Swiss longevity company Maximon, which recently launched an investment of CHF 100 million ($ 108 million), and the Swiss Longevity Science Foundation, which has pledged $ 1 billion in longevity research over 10 years. .

Other investment funds and holdings that have raised billions of dollars together include:

The introduction of these and many other means shows a tremendous amount of interest and money that is just beginning to support the science of longevity.

These investment funds will enable start-up biotechnology companies to develop life-changing technologies. As breakthroughs like xenotransplantation are becoming more common in healthcare, we will see huge amounts of money flowing into this industry.

As venture capitalists, we can see this trend in its infancy and begin to position ourselves right now.

Through my premium service Venture capital investor (expected to be publicly presented in the coming months), we have already made one investment in a private long-lived company that is positioned to generate high returns for investors …

And I will be watching many others soon.

At the date of publication, Cody Shirk did not hold (directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are the opinions of the writer who are the subject InvestorPlace.com Guidelines for publication.

By focusing on megatrends that will shape the future, Cody Shirk discovers generational wealth in the private investment space. To never miss a venture capital report, click here to subscribe.

MY NUMBER 1 RECOMMENDATION TO CREATE FULL TIME INCOME ONLINE: CLICK HERE

Leave a Comment

error: Content is protected !!